HK1 (Hexokinase 1)

Furthermore, the HK2 K144 mutation markedly enhances tumor cell glycolysis, fostering increased proliferation and migration both in vitro and in vivo. These findings underscore USP30 as a novel regulator of glycolysis in cancer cells via modulation of HK2 ubiquitination dynamics, suggesting its potential as a therapeutic target in cancer metabolism.

siRNA@EVs achieved significant HSPD1 silencing, effectively inhibiting the proliferation and metastasis of PCa cells, and blocking xenografts tumor growth in nude mice with safety. siRNA@EVs targeting HSPD1 demonstrate precision therapeutic potential with robust efficacy and safety, offering a novel approach for targeted therapy in PCa.

[198Au]Auranofin (c.a.) represents a stable and effective radiogold-based radiopharmaceutical agent, offering redox-targeted cytotoxicity alongside β⁻ emission mediated cell death and γ emission based imaging potential. These findings highlight c.a. [198Au]Auranofin as a promising radiogold-based theranostic candidate, offering dual capabilities in targeted cytotoxicity and nuclear imaging. While the in vitro results are encouraging, further in vivo and translational studies are warranted to fully evaluate its clinical potential in nuclear medicine guided cancer therapy.

The hexokinase activity of HKDC1 is also insensitive to Dinaciclib, a pan cyclin-dependent kinase inhibitor that reportedly disrupts the ability of nuclear localized HKDC1 to phosphorylate retinoblastoma-binding protein 5...An HKDC1 variant associated with retinitis pigmentosa, T58M, displays a modest, but statistically significant 2-fold decrease in catalytic efficiency (kcat/Km,glucose) compared to the wild-type enzyme. Together, our results provide a detailed functional characterization of recombinant HKDC1 and set the stage for investigating the link between HKDC1 catalysis and human disease.

Clinicians should suspect pseudohypoglycemia when glucose readings are critically low but the patient lacks corresponding symptoms, especially in patients pursuing alternative medicine. Whipple's Triad remains vital in differentiating true hypoglycemia from laboratory artifact, preventing unnecessary escalation of care.

Moreover, in the cancer cells treated with PHG or CUR-NEM, a significant reduction in glycolysis due to the inhibition of hexokinase activity was detected. These findings show that both PHG and CUR-NEM prevent metastasis in a preclinical animal model and link this ability to the inhibition of hexokinase 2, highlighting their potential significance as cancer therapeutics.

These findings establish DHT as a promising therapeutic agent for HCC by targeting PGAM1 degradation and disrupting glycolysis. The study provides a mechanistic framework for developing plant-derived therapeutics targeting metabolic pathways in liver cancer.

P=N/A, N=1500, Withdrawn, Lyell McEwin Hospital | Not yet recruiting --> Withdrawn

Platinum(II) complexes such as cisplatin, among a few others, are well-known anticancer metal-based drugs approved for clinical use...These approaches were based on protein expression analysis and thermal proteome profiling, respectively. Data obtained for the Pt(IV)-lonidamine complex revealed regulation of proteins involved in the glucose metabolic process associated with lonidamine, further supporting the multiaction mechanism of this prodrug action.

17β-estradiol mediates its effects on Jurkat E6.1 cells in vitro through receptor-subtype dependent and independent mechanisms involving metabolic enzymes (hexokinase, pyruvate kinase, citrate synthase), cytokines (IL-6), nitric oxide, and signaling molecules (p-Akt).

In vivo experiments corroborate our findings, revealing that neurturin blockade effectively halts pancreatic cancer progression and synergizes with RET inhibitors. Our research underscores neurturin as a promising therapeutic target for the treatment of pancreatic cancer.

Paclitaxel cytotoxicity independently causes lower OSI in all IKA-treated groups as compared to controls even though OSI is elevated in IKA groups compared to control...Partial thromboplastin time results also showed that IKA-treated cells had longer TF activation duration. A potential indirect association of HK-2 inhibition and TF regulation in breast cancer cells is put forward in this study by presenting IKA's bioactivation of breast cancer in all gene, protein, and enzyme levels.